Interestingly, simvastatin, a drug that lowers cholesterol levels by inhibiting a key enzyme in cholesterol synthesis (HMG-CoA reductase), has been shown to interfere with cancer stem cell plasticity and reduce metastasis in ovarian cancer [28], and statin use has been associated with a lower risk of both serous and non-serous types of ovarian carcinoma [29]. Here, HMGCR is linked to ovarian carcinoma.